ACTRN12606000495527
Not yet recruiting
Phase 2
Efficacy of Abbreviated Course Rituximab for Treatment of Auto-immune Disease Refractory to Standard Immunosuppressive Therapy to improve response rate and durability of response
Melbourne Health - The Royal Melbourne Hospital0 sites30 target enrollmentDecember 1, 2006
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Auto-immune disorders
- Sponsor
- Melbourne Health - The Royal Melbourne Hospital
- Enrollment
- 30
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Auto\-immune disease refractory to or intolerant of conventional immunosuppressive therapy, Informed consent.
Exclusion Criteria
- •Hepatitis B or C positivity.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPTHROMBOTIC THROMBOCYTOPENIC PURPURAMedDRA version: 9.1Level: LLTClassification code 10037562EUCTR2010-018794-38-ITFONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Active, not recruiting
Phase 1
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVASEUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE TrialJPRN-jRCT2041180037Iijima Masahiro25